Health Condition 1: N979- Female infertility, unspecified
Conditions
Interventions
Intervention1:
Personalised immunomodulatory treatment strategies: Personalized immunomodulatory treatment strategies offered to women with repeated implantation failure and identified HLA KIR mismat
Sponsors
Dr Neeta Singh
Eligibility
Inclusion criteria
Inclusion criteria: Age from 21 to 35 years. Women diagnosed with RIF (defined as failure to achieve pregnancy after at least two embryo transfers with high quality embryos). Couples undergoing infertility evaluation and treatment. Both partners providing informed consent for genetic testing.
Exclusion criteria
Exclusion criteria: Women with known uterine abnormalities, thrombophilia, or autoimmune disorders. Cases with chromosomal abnormalities detected in either partner.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of HLA Class I and II mismatch with KIR genotypes in women with repeated implantation failure, and implantation rate after personalized immunomodulatory treatment in mismatch couplesTimepoint: Time Points: Baseline, 4 weeks, 8 weeks Baseline (before IVF cycle), 4 weeks after embryo transfer (biochemical pregnancy), and 8 weeks after embryo transfer (clinical pregnancy with cardiac activity) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Distribution of activating & inhibitory KIR genotypes in repeated implantation failures & their association with specific HLA alleles. 2.Implantation rate & Clinical pregnancy rate after personalised treatment in mismatch couples. 3. Comparing the prevalence of HLA-C-KIR mismatch among the fertile controls & RIF patients Timepoint: 1. At baseline 2. At 12 weeks. 3. At study completion | — |
Countries
India
Contacts
Public ContactDr Neeta Singh
All India Institute of Medical Sciences (AIIMS), New Delhi
Outcome results
None listed